Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing
Reexamination Certificate
2004-12-24
2009-08-04
Zara, Jane (Department: 1635)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
C424S009100, C424S009200, C435S069200, C435S194000
Reexamination Certificate
active
07569536
ABSTRACT:
The present invention provides: (1) antiviral agents that act by reducing or inhibiting the activity of SR proteins, more specifically, (i) antiviral agents that act by enhancing dephosphorylation of SR proteins, and (ii) antiviral agents that act by inhibiting proteins that phosphorylate SR proteins; (2) antiviral agents that act by inhibiting the expression of SR proteins, and (3) antiviral agents that act by activating proteins that antagonize SR proteins. The present invention also provides compounds that inhibit SRPKs, which phosphorylate SR proteins. Such compounds inhibit the activity of SR proteins and have antiviral activities. Various new viruses including SARS have emerged, and thus the present invention provides long-lasting broad-spectrum antiviral agents applicable to new viruses.
REFERENCES:
patent: 5707987 (1998-01-01), Nakagawa et al.
patent: 2006/0094081 (2006-05-01), Schubert et al.
patent: 1-151593 (1989-06-01), None
patent: 7-503966 (1995-04-01), None
patent: 2000-510865 (2000-08-01), None
patent: 2001-505193 (2001-04-01), None
patent: 2002-179651 (2002-06-01), None
patent: WO 02/02524 (2002-01-01), None
patent: WO 02/094796 (2002-11-01), None
patent: WO 2004/096795 (2003-04-01), None
Gendelman et al., AIDS, Bol. 4, No. 2, pp. 221-228 (1990).
Bridge et al., “Adenovirus Early Region 4 and Viral DNA Synthesis,”Virology. 193:794-801 (1993).
Daub et al., “Identification of SRPK1 and SRPK2 as the Major Cellular Protein Kinases Phosphorylationg Hepatitis B Virus Core Protein,”J. of Virology. 76:8124-8137 (2002).
Furman et al., “Phosphorylation of 3′-azido-3′-deoxythymidine and selective interaction of the 5′-triphosphate with human immunodeficiency virus reverse transcriptase,”Proc. Natl. Acad. Sci. USA. 83:8333-8337 (1986).
Huang et al., “Functional inactivation of the SR family of splicing factors during a vaccinia virus infection,”EMBO Reports. 3:1088-1093 (2002).
Kanopka et al. “Regulation of Adenovirus Alternative RNA Splicing by Dephosphorylation of SR Proteins,”Nature. 393:185-187 (1998).
Kuczynski et al., “Synthesis of New 4 and 5 Disubstituted Isothiazoles,”Polish J. of Pharmacology and Pharmacy. 36:485-491 (1984).
Reedijk et al., “Safety, Pharmacokinetics, and Antiviral Activity of A77003, a C2Symmetry-Based Human Immunodeficiency Virus Protease Inhibitor,”Antimicrobial Agents and Chemotherapy. 39:1559-1564 (1995).
ChemStar Product List, Order No. CHS 2726403, CAS Registry No. 494830-83-0, Apr. 24, 2003, Chemcats Accession No. 2003:2093953.
ChemStar Product List, Order No. CHS 2726421, CAS Registry No. 496012-09-0, Apr. 24, 2003, Chemcats Accession No. 2003:2093955.
ChemStar Product List, Order No. CHS 2726457, CAS Registry No. 672919-05-0, Apr. 24, 2003, Chemcats Accession No. 2004:2166987.
ChemStar Product List, Order No. CHS 2726514, CAS Registry No. 674360-18-0, Apr. 24, 2003, Chemcats Accession No. 2004:2167022.
Fukuhara Takeshi
Hagiwara Masatoshi
Hosoya Takamitsu
Suzuki Masa-aki
Hagiwara Masatoshi
Klarquist & Sparkman, LLP
Zara Jane
LandOfFree
Method for controlling SR protein phosphorylation, and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for controlling SR protein phosphorylation, and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for controlling SR protein phosphorylation, and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4089763